文献速递类风湿关节炎

阿达木单抗生物类似药PF-06410293治疗活动性类风湿关节炎第26-52周随机研究:含从参照药转换治疗

Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26-52, including a treatment switch from reference ADL to PF-06410293.
PubMed 文献 · RMD Open · 2021-01-01

这项多国双盲随机研究比较了阿达木单抗生物类似药PF-06410293(ADL-PF)与欧盟参照阿达木单抗(ADL-EU)治疗活动性类风湿关节炎的长期疗效、安全性、免疫原性和药代动力学,并评估第26周从ADL-EU盲法转换至ADL-PF的影响。第52周时各组ACR20应答率相当,深度应答指标和HAQ-DI维持稳定,不良事件和抗药抗体阳性率组间无临床意义差异,转换治疗未影响上述结果。

要点

  • 第52周ACR20应答率:ADL-PF/ADL-PF组82.7%,ADL-EU/ADL-EU组79.3%,ADL-EU/ADL-PF组84.3%。
  • 第26周从ADL-EU盲法转换至ADL-PF后,疗效、安全性和免疫原性至第52周维持稳定。
  • 不良事件发生率组间无临床意义差异,抗药抗体阳性率总体相当。

核心结论

  • ADL-PF与ADL-EU的疗效、安全性、免疫原性和药代动力学相似并维持至第52周,第26周盲法转换治疗未影响这些结果。

研究设计与样本

  • 多国双盲研究,活动性RA患者初始随机接受ADL-PF或ADL-EU治疗26周(TP1)。
  • TP2(第26-52周)开始时,ADL-EU组患者盲法1:1再随机分配至继续ADL-EU(n=135)或转换至ADL-PF(n=134),ADL-PF组继续盲法治疗(n=283)。

主要发现

  • TP2期间所有访视时治疗组间ACR20应答率相当。
  • 第52周ACR20应答率:ADL-PF/ADL-PF组82.7%,ADL-EU/ADL-EU组79.3%,ADL-EU/ADL-PF组84.3%。
  • 其他深度应答指标(ACR50/70、ACR/EULAR定义的缓解、EULAR良好应答、基于高敏C反应蛋白的DAS28<2.6)和HAQ-DI在TP2期间维持且组间相当。
  • 治疗中出现的不良事件发生率:ADL-PF/ADL-PF组43.5%,ADL-EU/ADL-EU组44.4%,ADL-EU/ADL-PF组38.3%,组间安全性特征无临床意义差异。
  • 抗药抗体阳性率总体相当:ADL-PF/ADL-PF组47.3%,ADL-EU/ADL-EU组54.1%,ADL-EU/ADL-PF组45.9%。

关键数值与推荐

  • 第52周ACR20应答率:ADL-PF/ADL-PF组82.7%,ADL-EU/ADL-EU组79.3%,ADL-EU/ADL-PF组84.3%。
  • 治疗中出现的不良事件发生率:ADL-PF/ADL-PF组43.5%,ADL-EU/ADL-EU组44.4%,ADL-EU/ADL-PF组38.3%。
  • 抗药抗体阳性率:ADL-PF/ADL-PF组47.3%,ADL-EU/ADL-EU组54.1%,ADL-EU/ADL-PF组45.9%。

临床怎么用

  • 活动性RA患者使用ADL-EU治疗26周后转换至ADL-PF,疗效、安全性和免疫原性至第52周维持稳定。
  • ADL-PF与ADL-EU的长期疗效和安全性特征相似,支持二者互换使用。

局限性

  • 原文摘要未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the efficacy, safety, immunogenicity and pharmacokinetics of biosimilar adalimumab (ADL) PF-06410293 (ADL-PF; adalimumab-afzb) versus EU-sourced reference ADL (ADL-EU) in patients with active rheumatoid arthritis (RA) on longer-term treatment and after being switched from ADL-EU to ADL-PF. METHODS: In this multinational, double-blind study, patients with active RA were initially randomised to ADL-PF or ADL-EU for 26 weeks (treatment period (TP) 1). At the start of TP2 (weeks 26-52), patients in the ADL-EU arm were blindly re-randomised 1:1 to remain on ADL-EU (ADL-EU/ADL-EU; n=135) or switched to ADL-PF (ADL-EU/ADL-PF; n=134); patients receiving ADL-PF continued blinded treatment (ADL-PF/ADL-PF; n=283). RESULTS: The American College of Rheumatology 20% improvement (ACR20) response rates were comparable between treatment groups at all visits during TP2. At week 52, ACR20 response rates were 82.7% (ADL-PF/ADL-PF), 79.3% (ADL-EU/ADL-EU) and 84.3% (ADL-EU/ADL-PF). Other measures of deep response (ACR50/70, ACR/EULAR-defined remission, EULAR good response, and Disease Activity Score in 28 Joints Based on High-Sensitivity C-Reactive Protein <2.6) and Health Assessment Questionnaire-Disability Index were maintained over TP2 and comparable between groups. Treatment-emergent adverse events were reported in 43.5% (ADL-PF/ADL-PF), 44.4% (ADL-EU/ADL-EU) and 38.3% (ADL-EU/ADL-PF) of patients; there were no clinically meaningful differences in the safety profiles between groups. The percentage of patients who were antidrug antibody positive was comparable overall among ADL-PF/ADL-PF (47.3%), ADL-EU/ADL-EU (54.1%) and ADL-EU/ADL-PF (45.9%). CONCLUSIONS: The similar efficacy, safety, immunogenicity and pharmacokinetics of ADL-PF and ADL-EU, maintained up to week 52, were unaffected by blinded treatment switch from ADL-EU to ADL-PF at week 26. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov identifier: NCT02480153; EudraCT number: 2014-000352-29.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Fleischmann RM, Alvarez DF, Bock AE, et al. Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26-52, including a treatment switch from reference ADL to PF-06410293. RMD Open. 2021. PMID: 33883254. doi:10.1136/rmdopen-2021-001578

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。